BCAB
Price
$0.67
Change
+$0.04 (+6.35%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
36.99M
40 days until earnings call
NVO
Price
$55.61
Change
-$0.43 (-0.77%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
261.3B
40 days until earnings call
Interact to see
Advertisement

BCAB vs NVO

Header iconBCAB vs NVO Comparison
Open Charts BCAB vs NVOBanner chart's image
BioAtla
Price$0.67
Change+$0.04 (+6.35%)
Volume$4.2K
Capitalization36.99M
Novo-Nordisk A/S
Price$55.61
Change-$0.43 (-0.77%)
Volume$73.5K
Capitalization261.3B
BCAB vs NVO Comparison Chart in %
Loading...
BCAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCAB vs. NVO commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCAB is a StrongBuy and NVO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (BCAB: $0.63 vs. NVO: $56.04)
Brand notoriety: BCAB and NVO are both not notable
BCAB represents the Biotechnology, while NVO is part of the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BCAB: 68% vs. NVO: 91%
Market capitalization -- BCAB: $36.99M vs. NVO: $261.3B
BCAB [@Biotechnology] is valued at $36.99M. NVO’s [@Pharmaceuticals: Major] market capitalization is $261.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $640.6B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B. The average market capitalization across the [@Pharmaceuticals: Major] industry is $87.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCAB’s FA Score shows that 0 FA rating(s) are green whileNVO’s FA Score has 2 green FA rating(s).

  • BCAB’s FA Score: 0 green, 5 red.
  • NVO’s FA Score: 2 green, 3 red.
According to our system of comparison, NVO is a better buy in the long-term than BCAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCAB’s TA Score shows that 5 TA indicator(s) are bullish while NVO’s TA Score has 4 bullish TA indicator(s).

  • BCAB’s TA Score: 5 bullish, 4 bearish.
  • NVO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, BCAB is a better buy in the short-term than NVO.

Price Growth

BCAB (@Biotechnology) experienced а -8.84% price change this week, while NVO (@Pharmaceuticals: Major) price change was -9.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +51.46%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.07%. For the same industry, the average monthly price growth was -0.30%, and the average quarterly price growth was +12.81%.

Reported Earning Dates

BCAB is expected to report earnings on Nov 05, 2025.

NVO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Major (-1.07% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVO($261B) has a higher market cap than BCAB($37M). BCAB YTD gains are higher at: 6.546 vs. NVO (-33.056). NVO has higher annual earnings (EBITDA): 154B vs. BCAB (-63.02M). NVO has more cash in the bank: 18.9B vs. BCAB (18.2M). BCAB has less debt than NVO: BCAB (6.05M) vs NVO (99.3B). NVO has higher revenues than BCAB: NVO (312B) vs BCAB (11M).
BCABNVOBCAB / NVO
Capitalization37M261B0%
EBITDA-63.02M154B-0%
Gain YTD6.546-33.056-20%
P/E RatioN/A14.19-
Revenue11M312B0%
Total Cash18.2M18.9B0%
Total Debt6.05M99.3B0%
FUNDAMENTALS RATINGS
NVO: Fundamental Ratings
NVO
OUTLOOK RATING
1..100
71
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
PROFIT vs RISK RATING
1..100
78
SMR RATING
1..100
15
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BCABNVO
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
45%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
59%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
62%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 9 days ago
67%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
60%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
50%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
BCAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NMB25.550.30
+1.19%
Simplify National Muni Bond ETF
SHY82.84-0.07
-0.08%
iShares 1-3 Year Treasury Bond ETF
QTJL37.82-0.07
-0.18%
Innovator Growth Accelerated Pls ETF Jul
TSME41.04-0.44
-1.06%
Thrivent Small-Mid Cap Equity ETF
FBL45.28-1.45
-3.10%
GraniteShares 2x Long META Daily ETF

BCAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCAB has been loosely correlated with AXON. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if BCAB jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCAB
1D Price
Change %
BCAB100%
+3.79%
AXON - BCAB
41%
Loosely correlated
+2.02%
KYMR - BCAB
39%
Loosely correlated
+2.35%
VCYT - BCAB
38%
Loosely correlated
+0.43%
CTMX - BCAB
38%
Loosely correlated
+17.84%
GALT - BCAB
36%
Loosely correlated
-2.95%
More

NVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVO has been closely correlated with NONOF. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVO jumps, then NONOF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVO
1D Price
Change %
NVO100%
-4.60%
NONOF - NVO
70%
Closely correlated
-4.77%
TECH - NVO
36%
Loosely correlated
-1.44%
GMAB - NVO
35%
Loosely correlated
-2.07%
BCAB - NVO
33%
Loosely correlated
+3.79%
MRK - NVO
32%
Poorly correlated
-2.60%
More